Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration

Purpose. To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration. Methods. This retrospective st...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Ophthalmol
Hlavní autoři: Griffin, David R., Richmond, Preston P., Olson, John C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi Publishing Corporation 2014
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258314/
https://ncbi.nlm.nih.gov/pubmed/25505976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/497178
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky